8-K: American Oncology Network Reports 20% Revenue Growth in Q1 2024, Despite Increased Net Loss

American Oncology Network (AONC) announced a 20% increase in revenue for the first quarter of 2024, driven by patient encounter growth, but also reported a significant increase in net loss and a decrease in adjusted EBITDA.

Summary

• American Oncology Network (AONC) reported a revenue of $364.3 million for the first quarter of 2024, a 20% increase compared to $303.7 million in the same period last year.
• The revenue growth was primarily due to a 7.1% increase in patient encounters, which contributed $59.7 million to patient service revenue.
• However, this growth was partially offset by $4.1 million in implicit price concessions related to a billing system transition.
• The cost of revenue increased by 27.4% to $354.9 million, mainly due to higher drug and medical supply costs, and included $13.3 million in equity-based compensation.
• Net loss before non-controlling interest was $24.9 million, a significant increase from a $1.5 million loss in the first quarter of 2023.
• Adjusted EBITDA decreased to $2.0 million from $4.1 million in the prior year's first quarter.
• The company had total liquidity of $132.7 million as of March 31, 2024, including $74.9 million in cash and cash equivalents.
• Net cash provided by operating activities was $45.1 million, which was influenced by a $48.3 million deferral of drug payments due to the Change Healthcare issue.

Sentiment

Score: 4

Explanation: While the company shows strong revenue growth, the significant increase in net loss and decrease in adjusted EBITDA, along with the impact of billing system issues and payment deferrals, create a negative sentiment. The positive expansion is overshadowed by financial challenges.

Positives

• The company achieved a substantial 20% increase in revenue year-over-year.
• Patient encounters grew by a solid 7.1%, indicating strong demand for services.
• AONC successfully expanded its network by adding 17 new providers.
• The company expanded its market presence in Texas and Maryland.
• The company has a total liquidity of $132.7 million.

Negatives

• The net loss before non-controlling interest significantly increased to $24.9 million.
• Adjusted EBITDA decreased by $2.1 million, falling to $2.0 million.
• Cost of revenue increased by 27.4%, driven by higher drug and medical supply costs.
• The company experienced $4.1 million in implicit price concessions due to a billing system transition.
• A $48.3 million deferral of drug payments will negatively impact cash flow in the second quarter of 2024.

Risks

• The transition to a new billing system resulted in $4.1 million in implicit price concessions, impacting revenue.
• Increased drug and medical supply costs are driving up the cost of revenue.
• The deferral of $48.3 million in drug payments will negatively impact cash flow in the second quarter of 2024.
• The company's net loss has significantly increased year-over-year.
• The decrease in adjusted EBITDA indicates potential challenges in maintaining profitability.

Future Outlook

The company expects the $48.3 million deferral of drug payments to negatively impact operating cash flow in the second quarter of 2024. The company also mentioned continued expansion through acquisitions and partnerships.

Management Comments

• Todd Schonherz, AONC chief executive officer, stated that they delivered strong revenue growth in the first quarter, continuing their momentum into 2024.
• He also highlighted the acquisitions that grew the AON footprint and the expansion in Texas and Maryland markets.
• The CEO mentioned the launch of Meaningful Insights Biotech Analytics (MiBA) as an innovative healthcare technology startup.

Industry Context

The announcement reflects the ongoing trend of consolidation and expansion in the oncology services sector, with companies like AONC focusing on community-based care and leveraging technology to improve patient outcomes. The company is also expanding into new markets and adding new providers to its network.

Comparison to Industry Standards

• While AONC's revenue growth of 20% is strong, the significant increase in net loss and decrease in adjusted EBITDA are concerning when compared to industry peers.
• Companies like US Oncology and McKesson Specialty Health, which also operate in the oncology management space, typically aim for consistent profitability alongside revenue growth.
• The impact of the billing system transition and the deferral of drug payments are specific challenges for AONC and not necessarily reflective of broader industry trends.
• The company's expansion into new markets is consistent with industry trends, but its financial performance needs to improve to align with industry benchmarks.

Related Party Transactions

• The document mentions related party inventory expense of $310,877 and $178,166 for the three months ended March 31, 2024 and 2023, respectively.
• The document mentions related party rent of $706 and $679 for the three months ended March 31, 2024 and 2023, respectively.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased adjusted EBITDA.
• Employees may be affected by the company's financial performance and any potential cost-cutting measures.
• Patients may benefit from the company's expansion and increased access to care.
• Suppliers may be impacted by the deferral of drug payments.

Next Steps

• The company will host a conference call on May 16, 2024, to discuss the first quarter 2024 results.
• The company will need to address the issues with the billing system transition and the deferred drug payments.
• The company will continue to focus on expansion through acquisitions and partnerships.

Key Dates

Keywords

oncology, revenue, EBITDA, patient encounters, healthcare, financial results, net loss, billing system, provider network, liquidity